Vaxart (OTCMKTS:VXRT – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.04), Zacks reports. The company had revenue of $10.62 million for the quarter, compared to the consensus estimate of $27.20 million. Vaxart had a net margin of 15.88% and a return on equity of 53.04%.
Vaxart Price Performance
Shares of VXRT stock traded up $0.01 during trading hours on Friday, reaching $0.37. 311,366 shares of the company traded hands, compared to its average volume of 288,448. The company has a market cap of $90.17 million, a P/E ratio of 2.85 and a beta of 1.15. Vaxart has a 12-month low of $0.33 and a 12-month high of $0.84. The firm has a 50-day moving average price of $0.45 and a 200 day moving average price of $0.58.
About Vaxart
Vaxart, Inc is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.
Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza.
Featured Stories
- Five stocks we like better than Vaxart
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
